185 related articles for article (PubMed ID: 28984179)
1. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
Cohan S; Kappos L; Giovannoni G; Wiendl H; Selmaj K; Havrdová EK; Rose J; Greenberg S; Phillips G; Ma W; Wang P; Lima G; Sabatella G
Mult Scler; 2018 Dec; 24(14):1883-1891. PubMed ID: 28984179
[TBL] [Abstract][Full Text] [Related]
2. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
[TBL] [Abstract][Full Text] [Related]
3. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
4. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Benedict RH; Cohan S; Lynch SG; Riester K; Wang P; Castro-Borrero W; Elkins J; Sabatella G
Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
[TBL] [Abstract][Full Text] [Related]
5. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
11. Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Giovannoni G; Wiendl H; Turner B; Umans K; Mokliatchouk O; Castro-Borrero W; Greenberg SJ; McCroskery P; Giannattasio G
Mult Scler; 2018 Nov; 24(13):1725-1736. PubMed ID: 28914581
[TBL] [Abstract][Full Text] [Related]
12. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab in multiple sclerosis.
Perez-Miralles FC
Rev Neurol; 2018 Apr; 66(8):271-282. PubMed ID: 29645071
[TBL] [Abstract][Full Text] [Related]
14. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang L; Zhan SY; Xia Y
Cochrane Database Syst Rev; 2012 Apr; (4):CD008127. PubMed ID: 22513956
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
Newsome SD; Kieseier BC; Liu S; You X; Kinter E; Hung S; Sperling B
Ther Adv Neurol Disord; 2017 Jan; 10(1):41-50. PubMed ID: 28450894
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal effects of daclizumab treatment of multiple sclerosis.
Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
